Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multiregional, Open-Label Phase 3 Clinical Trial of ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer

NCT07756645 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07756645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07756645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multiregional, Open-Label Phase 3 Clinical Trial of ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 22, 2026
Completion date
December 31, 2029
Enrollment
940 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer